Cong Chen

985 total citations
37 papers, 353 citations indexed

About

Cong Chen is a scholar working on Statistics and Probability, Management Science and Operations Research and Immunology. According to data from OpenAlex, Cong Chen has authored 37 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Statistics and Probability, 15 papers in Management Science and Operations Research and 8 papers in Immunology. Recurrent topics in Cong Chen's work include Statistical Methods in Clinical Trials (27 papers), Optimal Experimental Design Methods (14 papers) and Biosimilars and Bioanalytical Methods (7 papers). Cong Chen is often cited by papers focused on Statistical Methods in Clinical Trials (27 papers), Optimal Experimental Design Methods (14 papers) and Biosimilars and Bioanalytical Methods (7 papers). Cong Chen collaborates with scholars based in United States, China and United Kingdom. Cong Chen's co-authors include Linda Sun, Eric H. Rubin, Xiaoyun Li, Heng Zhou, Devan V. Mehrotra, Archie Tse, Robert A. Beckman, Cai Wu, Keaven M. Anderson and Jianqi Hao and has published in prestigious journals such as Blood, Clinical Cancer Research and Statistics in Medicine.

In The Last Decade

Cong Chen

35 papers receiving 342 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cong Chen United States	11	174	78	68	60	59	37	353
Kyung Mann Kim United States	10	99 0.6×	69 0.9×	25 0.4×	38 0.6×	102 1.7×	16	363
Sally Clive United Kingdom	13	76 0.4×	38 0.5×	62 0.9×	44 0.7×	190 3.2×	30	500
Carl‐Fredrik Burman Sweden	14	366 2.1×	143 1.8×	22 0.3×	38 0.6×	19 0.3×	34	584
NM Hylton United States	5	194 1.1×	44 0.6×	218 3.2×	68 1.1×	117 2.0×	9	519
Gautier Paux France	9	64 0.4×	30 0.4×	50 0.7×	110 1.8×	115 1.9×	26	394
Thomas Gwise United States	10	100 0.6×	22 0.3×	56 0.8×	37 0.6×	96 1.6×	24	316
Jeff Maca United States	8	237 1.4×	84 1.1×	17 0.3×	26 0.4×	30 0.5×	16	525
Y. H. George United States	8	308 1.8×	144 1.8×	27 0.4×	35 0.6×	30 0.5×	10	420
Emmanuel Zuber Switzerland	8	188 1.1×	77 1.0×	42 0.6×	209 3.5×	148 2.5×	15	458
Tie‐Hua Ng United States	8	117 0.7×	54 0.7×	18 0.3×	32 0.5×	35 0.6×	16	274

Countries citing papers authored by Cong Chen

Since Specialization

Citations

This map shows the geographic impact of Cong Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cong Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cong Chen more than expected).

Fields of papers citing papers by Cong Chen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cong Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cong Chen. The network helps show where Cong Chen may publish in the future.

Co-authorship network of co-authors of Cong Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Cong Chen. A scholar is included among the top collaborators of Cong Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cong Chen. Cong Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shord, Stacy S., Cong Chen, Jin Y. Jin, et al.. (2025). FDA–AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials. Clinical Cancer Research. 31(23). 4891–4898.

Liu, Jian, Cong Chen, Honggang Chen, et al.. (2024). Patient-Reported Outcomes and Complication Profiles of Implant-Based Breast Reconstruction in Patients With Postmastectomy Radiation Therapy. Annals of Plastic Surgery. 93(1). 22–29. 2 indexed citations

Huang, Mo, Cong Chen, & Linda Sun. (2023). Statistical Interpretation and Comparison of Waterfall Plots. JCO Clinical Cancer Informatics. 7(7). e2300132–e2300132.

Chen, Cong, Linda Sun, & Xuekui Zhang. (2023). A promising biomarker adaptive Phase 2/3 design – Explained and expanded. Contemporary Clinical Trials Communications. 36. 101229–101229. 1 indexed citations

Ding, Xinfa, et al.. (2023). Leadless pacemaker implantation and azygos continuation in the inferior vena cava: a case description. Quantitative Imaging in Medicine and Surgery. 13(4). 2751–2757. 2 indexed citations

Jing, Naimin, Fang Liu, Cai Wu, Heng Zhou, & Cong Chen. (2022). An optimal two-stage exploratory basket trial design with aggregated futility analysis. Contemporary Clinical Trials. 116. 106741–106741. 2 indexed citations

Jemielita, Thomas, Xiaoyun Li, Thomas Burke, et al.. (2021). Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non–small-Cell Lung Cancer Treated With Pembrolizumab. JCO Clinical Cancer Informatics. 5(5). 849–858. 2 indexed citations

Zhou, Heng, Cong Chen, Linda Sun, & Zhen Zeng. (2021). A novel framework of Bayesian optimal interval design for phase I trials with late-onset toxicities. Contemporary Clinical Trials. 105. 106404–106404. 2 indexed citations

Wu, Cai, et al.. (2021). Optimal one-stage design and analysis for efficacy expansion in Phase I oncology trials. Clinical Trials. 18(6). 673–680. 5 indexed citations

10.

Zhou, Heng, Cong Chen, Linda Sun, & Ying Yuan. (2020). Bayesian optimal phase II clinical trial design with time‐to‐event endpoint. Pharmaceutical Statistics. 19(6). 776–786. 15 indexed citations

11.

Chen, Cong, et al.. (2020). Extensions of the 2-in-1 adaptive design. Contemporary Clinical Trials. 95. 106053–106053. 9 indexed citations

12.

Hao, Jianqi, Cong Chen, Fangfang Wan, et al.. (2020). Prognostic Value of Pre-Treatment Prognostic Nutritional Index in Esophageal Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology. 10. 797–797. 31 indexed citations

13.

Zhou, Heng, et al.. (2019). Optimal two-stage designs for exploratory basket trials. Contemporary Clinical Trials. 85. 105807–105807. 15 indexed citations

14.

Dai, Shenghai, Dubravka Svetina, & Cong Chen. (2018). Investigation of Missing Responses in Q-Matrix Validation. Applied Psychological Measurement. 42(8). 660–676. 3 indexed citations

15.

Chen, Cong, et al.. (2018). Adaptive expansion of biomarker populations in phase 3 clinical trials. Contemporary Clinical Trials. 71. 181–185. 10 indexed citations

16.

Chen, Cong, Keaven M. Anderson, Devan V. Mehrotra, Eric H. Rubin, & Archie Tse. (2017). A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. Contemporary Clinical Trials. 64. 238–242. 41 indexed citations

17.

Chen, Cong, et al.. (2017). How many tumor indications should be initially screened in development of next generation immunotherapies?. Contemporary Clinical Trials. 59. 113–117. 11 indexed citations

18.

Hwang, Eunjoo, Jingwen Hu, Cong Chen, et al.. (2016). Development, Evaluation, and Sensitivity Analysis of Parametric Finite Element Whole-Body Human Models in Side Impacts. SAE technical papers on CD-ROM/SAE technical paper series. 60. 473–508. 35 indexed citations

19.

Hou, Zhibo, et al.. (2014). In Vitro and in Vivo Antitumor Evaluation of Berbamine for Lung Cancer Treatment. Asian Pacific Journal of Cancer Prevention. 15(4). 1767–1769. 38 indexed citations

20.

Chen, Cong, et al.. (2012). Testing superiority at interim analyses in a non‐inferiority trial. Statistics in Medicine. 31(15). 1531–1542. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact